0.9000
0.0000
(0.00%)
As of 8:34:30 AM GMT+1. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paul Pagano Ph.D. | CEO, Chief Scientific Officer & Executive Director | 241.91k | -- | 1985 |
| Mr. David M. Anderson | CFO, Company Secretary & Executive Director | 182.47k | -- | 1963 |
LungLife AI, Inc.
2545 West Hillcrest Drive
Suite 140
Thousand Oaks, CA 91320
United States
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 8
Description
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. LungLife AI, Inc. was incorporated in 2009 and is based in Thousand Oaks, California.
Corporate Governance
LungLife AI, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available